Research · Updated 17 Oct, 09:40 pm IST
Semaglutide reduced epigenetic signs of biological aging in a randomized trial
Why it matters for readers: Provides controlled clinical evidence that a widely used GLP-1 drug can affect DNA-based markers linked to aging.
- The trial was randomized, double-blind and placebo-controlled and included 108 adults with HIV-associated lipohypertrophy.1
- About half the participants received weekly semaglutide injections while the rest received placebo injections.1
- Researchers used multiple epigenetic clocks that measure DNA methylation to assess changes in biological aging over 32 weeks.1
- The analysis showed semaglutide slowed the accumulation of DNA-based markers of cellular aging compared with placebo.1
Get a brief like this every morning
Uzha reads hundreds of sources and gives you the stories that matter for your work, with every source linked. Free.
Get started